PMAIP1 and neoplasm: The results imply that deguelin is a well‐tolerated compound at the dose of 3 mg/kg, and the inhibitory effect of deguelin on the xenograft tumour growth may partly depend on the suppression of Bmi1 and the induction of Noxa expression.